Delpor, Inc.
Delpor is a clinical-stage biopharmaceutical company that utilizes innovative technologies to develop once-yearly therapies for chronic diseases, focusing on CNS conditions including Schizophrenia, Opioid Use Disorder, Spasticity, Parkinson’s, Alzheimer’s, and MS. The company develops drug delivery systems using proprietary technologies like PROZOR™ and NANOPORT™, enabling sustained release of drugs from small, non-mechanical, implantable devices. Their goal is to improve medication adherence, safety, efficacy, and patient convenience by providing long-acting, reversible, and smooth pharmacokinetic profiles for various therapeutics.
Industries
Nr. of Employees
small (1-50)
Delpor, Inc.
150 NORTH HILL DRIVE, SUITE 25, BRISBANE, CA 94005
Patents
Products
DLP-114 (risperidone implant)
Investigational subcutaneous implant delivering risperidone for maintenance therapy with a 6–12 month dosing period per implanted device; designed for smooth plasma levels and explantable if required.
DLP-160 (naltrexone implant)
Investigational subcutaneous implant formulation of naltrexone intended to provide 6–12 months of therapeutic exposure for opioid use disorder with the option for explantation to restore opioid responsiveness when needed.
DLP-208 (tizanidine implant)
Investigational subcutaneous implant intended to deliver tizanidine for 3–6 months to support maintenance therapy for moderate to severe spasticity via a minimally invasive, brief outpatient procedure.
DLP-414 (exenatide implant)
Investigational implant designed to deliver exenatide (a GLP-1 receptor agonist) for 3–12 months using a nanopore-based sustained-release approach to improve convenience and adherence for type 2 diabetes maintenance therapy.
DLP-119 (olanzapine implant)
Investigational matchstick-sized implant intended to deliver olanzapine for a 3-month duration using formulation strategies designed to reduce known safety risks and improve adherence versus current depot injections.
DLP-114 (risperidone implant)
Investigational subcutaneous implant delivering risperidone for maintenance therapy with a 6–12 month dosing period per implanted device; designed for smooth plasma levels and explantable if required.
DLP-160 (naltrexone implant)
Investigational subcutaneous implant formulation of naltrexone intended to provide 6–12 months of therapeutic exposure for opioid use disorder with the option for explantation to restore opioid responsiveness when needed.
DLP-208 (tizanidine implant)
Investigational subcutaneous implant intended to deliver tizanidine for 3–6 months to support maintenance therapy for moderate to severe spasticity via a minimally invasive, brief outpatient procedure.
DLP-414 (exenatide implant)
Investigational implant designed to deliver exenatide (a GLP-1 receptor agonist) for 3–12 months using a nanopore-based sustained-release approach to improve convenience and adherence for type 2 diabetes maintenance therapy.
DLP-119 (olanzapine implant)
Investigational matchstick-sized implant intended to deliver olanzapine for a 3-month duration using formulation strategies designed to reduce known safety risks and improve adherence versus current depot injections.
Services
Commercial licensing of internal implantable drug-delivery programs or platform technologies to partners for specific markets or indications.
Collaborative R&D arrangements to adapt implant delivery for external product candidates meeting specified attributes (high potency, poor oral bioavailability, benefit from steady plasma levels).
Pursuit of international partners to provide local market expertise for licensing and commercialization of implantable therapies outside the U.S.
Commercial licensing of internal implantable drug-delivery programs or platform technologies to partners for specific markets or indications.
Collaborative R&D arrangements to adapt implant delivery for external product candidates meeting specified attributes (high potency, poor oral bioavailability, benefit from steady plasma levels).
Pursuit of international partners to provide local market expertise for licensing and commercialization of implantable therapies outside the U.S.
Expertise Areas
- Implantable long-acting drug delivery
- Formulation development for sustained release
- Microfabrication of nanopore membranes
- Pharmacokinetic development and PK comparability
Key Technologies
- Zero-order sustained-release subcutaneous implants
- Microfabricated nanopore membranes
- Passive diffusion-based long-acting delivery
- Formulation using pH-regulating excipients for insoluble drugs
News & Updates
The company plans to conduct several trials with its drug-device combo in schizophrenia and opioid use disorder over the next couple of years.
Delpor has initiated and dosed the first patient in a phase 1b/2a clinical trial of DLP-114, a long-acting risperidone implant for schizophrenia maintenance therapy.
Delpor has dosed the first subjects in a phase 1 trial of DLP-160, a 6-12 month naltrexone implant for opioid use disorder.
Delpor received a grant from NIMH to develop a 3-month olanzapine implant to improve medication adherence and safety.
Delpor received a NIH grant to develop a 3-month risperidone implant to improve adherence in schizophrenia and bipolar disorder.
Delpor received a NIH grant to develop a 3-12 month exenatide implant for type 2 diabetes.
The company plans to conduct several trials with its drug-device combo in schizophrenia and opioid use disorder over the next couple of years.
Delpor has initiated and dosed the first patient in a phase 1b/2a clinical trial of DLP-114, a long-acting risperidone implant for schizophrenia maintenance therapy.
Delpor has dosed the first subjects in a phase 1 trial of DLP-160, a 6-12 month naltrexone implant for opioid use disorder.
Delpor received a grant from NIMH to develop a 3-month olanzapine implant to improve medication adherence and safety.
Delpor received a NIH grant to develop a 3-month risperidone implant to improve adherence in schizophrenia and bipolar disorder.
Delpor received a NIH grant to develop a 3-12 month exenatide implant for type 2 diabetes.